Australia's Securities Regulator to Probe ASX After Collapsed Blockchain Project
Australia's Securities and Investment Commission (ASIC) has turned to three of the country's most seasoned finance figures to probe the inner workings of the Australian Securities Exchange, including the exchange's doomed blockchain project.
ASIC launched the inquiry on June 16 over 'ongoing concerns' it and the Reserve Bank of Australia expressed about the exchange's ability to run stable and secure market plumbing.
Those concerns intensified when ASX scrapped a blockchain-based upgrade to its CHESS settlement engine in 2022, forcing a costly reset and drawing political heat. ASIC later sued ASX over making misleading statements on the project.
Rob Whitfield, a former Westpac chief risk officer and now a Commonwealth Bank director, will chair ASIC's panel. Joining him are Christine Holman, who sits on the boards of utility AGL and restaurant operator Collins Foods, and Guy Debelle, a Reserve Bank of Australia's former deputy governor.
The trio will inspect ASX's governance, technical capability, and risk controls and recommend fixes for any weak spots.
Their brief stretches across the entire ASX group, which handles more than A$6 billion ($3.92 billion) in trades each day.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
This Simble Solutions Insider Increased Their Holding In The Last Year
Looking at Simble Solutions Limited's (ASX:SIS ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The insider Amarandhar Kotha made the biggest insider purchase in the last 12 months. That single transaction was for AU$191k worth of shares at a price of AU$0.0043 each. So it's clear an insider wanted to buy, even at a higher price than the current share price (being AU$0.004). Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Amarandhar Kotha was the only individual insider to buy during the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! Check out our latest analysis for Simble Solutions Simble Solutions is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying. Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It appears that Simble Solutions insiders own 30% of the company, worth about AU$1.3m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment. The fact that there have been no Simble Solutions insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. Insiders own shares in Simble Solutions and we see no evidence to suggest they are worried about the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. While conducting our analysis, we found that Simble Solutions has 5 warning signs and it would be unwise to ignore them. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA
BRISBANE, Australia, June 25, 2025 /PRNewswire/ -- Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced Soft Tissue Sarcoma (STS). An Objective Response Rate (ORR) of 80% was achieved, based on the Best Observed Response (BOR) at any time during the study, indicating 8 out of 10 evaluable patients saw either complete ablation (100% reduction in volume) or partial ablation (≥30% reduction in volume) of treated tumours. 22 of the 27 (81%) injected tumours across all patients showed complete or partial ablation (14 showing complete ablation and 8 showing partial ablation). None of the 14 completely ablated tumours recurred at 6 months, indicating tigilanol tiglate may provide durable responses. QBiotics Group Limited (QBiotics) is pleased to announce final efficacy and safety data from the first of its two stage, Phase IIa clinical trial in patients with Soft Tissue Sarcoma (STS). STS is a rare type of cancer that generally forms as a painless lump (tumour) in any one of the soft tissues in the body. There were approximately 128,000 new cases of STS globally in 2023, with the incidence growing at 0.54% per year.[1] QBiotics' CEO and Managing Director, Stephen Doyle commented, "We are delighted with the outcomes from Stage 1 of our Phase IIa Soft Tissue Sarcoma trial. Tigilanol tiglate met both its primary and secondary endpoints and delivered patients an impressive 80% Objective Response Rate in injected tumours. Importantly, none of the 14 fully ablated (destroyed) tumours had recurred by the 6-month follow-up period, suggesting tigilanol tiglate may provide long-term benefit for patients. Given soft tissue sarcoma is a challenging cancer to treat, achieving this level of clinical activity is highly encouraging." "Our thanks to every trial patient, and also to the trial Investigators, Dr. Edmund Bartlett and his team at Memorial Sloan Kettering Cancer Center in New York. Given the positive results from Stage 1 of the trial – and compelling investigator reports that tigilanol tiglate may improve responses to systemic therapies in metastatic STS – we have moved ahead with the expansion arm of the study, announced late last year." Dr. Edmund Bartlett, Principal Trial Investigator at Memorial Sloan Kettering Cancer Center commented, "The clinical activity of tigilanol tiglate, which we observed in multiple types of soft tissue sarcoma, was encouraging. I look forward to expanding our experience with this treatment and determining how to integrate it into the care of patients with soft tissue sarcoma." ABOUT TRIAL QB46C-H07 QB46C-H07 (Clinical trial registration, NCT05755113) is a Phase IIa, open label, clinical trial evaluating the preliminary efficacy and safety of intratumoural tigilanol tiglate in patients with a range of advanced and/or metastatic STS. QB46C-H07 is being conducted in two stages: Stage 1 is a pilot trial in 10 patients. Stage 2 is an expansion trial. The results of Stage 1 are reported here. Eleven patients were administered tigilanol tiglate (0.5 mg tigilanol tiglate/cm3 tumour volume) to one or more of their tumours. Ten patients were included in the response evaluable population (where patients had a tumour assessment at both baseline and at 28 days post-treatment). The primary efficacy endpoint was Objective Response Rate (ORR) of injected tumours, compared to baseline. ORR was defined as the proportion of patients who achieved complete ablation (100% reduction in volume) or partial ablation (≥ 30% reduction in volume) of treated tumours and/or tumour segments following one or more treatments (up to 5 treatments) with tigilanol tiglate. Patients who achieved a ≥ 30% reduction in volume, irrespective of the number of treatments they received, were considered to have a response to tigilanol tiglate. Secondary endpoints include safety and tolerability assessments, and pharmacokinetics. Exploratory endpoints include local rate of recurrence at the injection site at 6 months post-initial injection, and assessment of tumour response in biopsy samples. Surgical specimens and blood samples were used to assess changes in tumour biomarkers. Efficacy and Safety Outcomes The ORR was 80% indicating 8 out of 10 evaluable patients achieved either complete or partial ablation of their treated tumours or tumour segments at any time during the study (Best Observed Response, BOR). There was a median of 2 treatments of tigilanol tiglate per patient (range 1 to 5). At the tumour level, 22 of 27 (81%) treated tumours showed either complete or partial responses as the Best Observed Response. 14 out of 27 tumours (52%) demonstrated complete ablation, while 8 out of 27 tumours (30%) demonstrated partial ablation. These results indicate a high level of efficacy for tigilanol tiglate in achieving complete or partial tumour ablation. Importantly, none of the complete responses (n=14) recurred by 6 months, the follow-up period, indicating tigilanol tiglate may provide durable responses. All 11 tigilanol tiglate treated patients were included in the safety evaluation. Tigilanol tiglate was well tolerated. Most of the Adverse Events (AEs) were expected and related to the local action of the drug (e.g. local pain, swelling, necrosis). Conclusions Overall, the study results indicate tigilanol tiglate is well tolerated and shows promising efficacy in reducing tumour volume, with 80% of patients experiencing complete (100%) ablation or partial (≥30%) ablation of their tumours. The absence of tumour recurrence in cases achieving a complete response further underscores tigilanol tiglate's potential as an effective treatment option for soft tissue sarcomas and possibly other solid tumours. The promising tumour responses reported here, together with observations that three patients exhibited better than expected responses to subsequent systemic therapy (as presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting in November 2024),[2] have supported the progression of the QB46C-H07 study to Stage 2. The trial expansion (referred to as Stage 2) aims to further investigate the clinical utility and therapeutic potential of tigilanol tiglate in patients with STS. Stage 2 of the trial is opening shortly at Memorial Sloan Kettering Cancer Center in New York, USA. References GlobalData®, American Cancer Society, Cancer Australia, Cancer Research UK, Canadian Cancer Society. Bartlett et al, 2024. The Connective Tissue Oncology Society (CTOS) Annual Meeting, Nov 13-16, 2024, San Diego, USA. NOTES FOR EDITORS ABOUT QBIOTICS QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialisation to harness the power of nature to treat diseases of high unmet need. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program. QBiotics' lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumours. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024. A veterinary formulation of tigilanol tiglate (STELFONTA®) is approved for the treatment of canine mast cell tumours (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA®. Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment. For more, head to: or LinkedIn. View original content to download multimedia: SOURCE QBiotics Group Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
2 hours ago
- Forbes
How Blockchain Is Reshaping Commerce, One Wallet At A Time
Jamie Elkaleh is the Chief Marketing Officer at Bitget Wallet. In the world of shopping, blockchain is emerging as an undeniable game changer; from enabling faster, borderless payments to reducing fees and improving transaction efficiency, the possibilities are endless and exciting. One of blockchain's most remarkable capabilities is facilitating true democratization, empowering businesses and individuals: Web3 provides merchants with lower costs and eliminates reliance on banks, offering relief from geographic, political and regulatory complications. It functions transparently; everything is available on a public ledger, allowing businesses and consumers a clear view for navigating the digital economy. It creates access to digital-first customers, as well as an opportunity to "bank the unbanked," helping those traditionally excluded from financial services due to restrictive requirements. Blockchain wallets are no longer just a more sophisticated version of electronic money. They serve an array of real-world purposes beyond just storing assets: Users can earn interest, shop and send instant, low-cost borderless payments—especially for remittances, which are growing rapidly worldwide. With Web3 and blockchain, transactions that used to take days and involve high fees can now happen in seconds with much lower costs. Blockchain is opening a world of user-friendly payment alternatives that challenge traditional financial systems—offering solutions that are cheaper, faster and more accessible. Reducing Barriers To Entry Of course, there are obstacles to inclusion. One of the biggest is the technological learning curve. That's something our company is actively working to address by providing educational resources in local communities. Even with traditional banking, accessibility is an issue. More and more high-street banks are closing down, and the days of walking into a branch and speaking to someone in person are disappearing. Everything is moving online and becoming automated, or shifting to rely on AI chatbots. Consequently, we counter the argument that blockchain is 'too complicated' by asserting that even traditional finance is becoming harder to navigate for certain demographics. We believe strongly that putting technology directly into communities and making it as easy as possible to use is both a business and ethical imperative. Creating pathways for the comprehension and use of blockchain technology allows companies not only to expand their user base but also to help these users (for instance, by minimizing issues like chargebacks, since blockchain transactions are transparent and verifiable by anyone). Companies whose business is blockchain should consider the fact that in order to gain maximum buy-in, it's essential to upskill and educate users—particularly those in local constituent communities—on how blockchain can empower their daily lives. The mission cannot be merely about introducing people to 'your' proprietary technology; rather, it should be viewed as providing them with tools they can actually, meaningfully use for their own financial betterment. For our company, this has meant not just working with individuals but also onboarding merchants, so they can learn to accept digital payments and, in doing so, realize a huge gain (eliminating high banking fees, streamlining operations). By educating them, we're helping them increase profitability and expand their customer base. We believe this education is part of our role; our success relies on users understanding the potential of these solutions. Revolutionary Trust And Accessibility One of the reasons it's so important that individuals and merchants understand blockchain is that it has changed commerce dramatically—particularly the way people shop. Blockchain enhances trust between producers, merchants and consumers. Companies like Walmart and IBM are already using enterprise blockchain solutions to track their supply chains internally. The next step is making that information public—allowing consumers to verify a product's entire journey from production to purchase, allowing them to assess everything from freshness to authenticity to ethical sourcing. Blockchain is bridging the gap between digital currencies and everyday shopping. Millions of people worldwide already own digital assets; now, thanks to new infrastructure, they can spend them seamlessly, with some high-street banks now accepting digital currency deposits into traditional banking applications. Increasingly, companies at the vanguard want to take things a step further, enabling users to shop directly with their digital assets. They can use digital currency-backed payment cards, earn interest like a regular bank account, access cashback rewards and even take advantage of installment plans. Now, with integrations like Apple Pay, digital payments are becoming just as straightforward as traditional banking methods—something that wasn't possible in the recent past. Best Practices For Implementation One major challenge we've been grappling with is the stigma around Web3 and blockchain technology. Unfortunately, we've recently seen senior global leaders publicly discussing the space in ways that don't always align with its core principles. Web3 isn't just about speculation or meme coins; there are incredible builders in this space solving real-world problems with blockchain, such as providing financial access to millions of people who have been excluded from traditional banking systems. The focus should be on tangible solutions and real-world utility rather than just the headlines. For business leaders who are new to blockchain-based payments, we have some recommended best practices: 1. Start with pilot programs. Test blockchain integrations on a small scale before full implementation. Learn from the process and build solutions tailored to your organization's needs. 2. Educate and train your teams. Employees should understand both the opportunities and the risks of blockchain. Reducing resistance and increasing capability through education will ensure smoother adoption. 3. Acknowledge the stigma. There's no denying that digital currency, Web3 and blockchain still carry a certain air of disrepute. Breaking that down through transparency and education is important to diminishing that sensibility. 4. Respect regulations. Having a strong legal team ensures compliance and reduces risk, even in strict regulatory environments. 5. Focus on scalability. Any blockchain solution must be able to handle growth efficiently, or why bother? 6. Partner with experienced providers. While no one is a true 'expert' in such a rapidly evolving space, working with trusted, knowledgeable partners is essential (and can help sidestep many rookie mistakes). The Benefit Of An Open Mindset One of the difficulties faced by many blockchain startups (which we've dealt with several times, in our organization) is not yielding to the pressure to scale as quickly as possible. We have to remind ourselves sometimes that there's a benefit to prioritizing education and growing the wider space. We also strive to maintain an open mindset. We acknowledge that we exist in a space wherein competitors are aiming to do similar things to what we do; we have to remind ourselves that if a user comes in, likes the technology and then chooses to go with one of our competitors, that's still a win for the space as a whole. Obviously, we believe in our product and our services and hope that users will recognize the value we provide. However, the key to driving mass adoption is not just having people purchase your proprietary solution but encouraging people to explore and use the technology more broadly. If people engage with Web3, have a positive experience and share that experience, the entire ecosystem wins. Forbes Communications Council is an invitation-only community for executives in successful public relations, media strategy, creative and advertising agencies. Do I qualify?
